Resyca

About Resyca

Resyca® is a joint venture between Bespak and Medspray that develops and manufactures innovative soft mist inhalers. We are redefining drug delivery through innovative soft mist inhalation and nasal spray technologies.

Our IP-protected platforms enable efficient lung delivery and targeted nasal administration, helping pharmaceutical and biotech partners differentiate their therapies and overcome key challenges in today’s OINDP development.

Proprietary technologies, including our Soft Mist Inhaler (PFSI) and Ultra Soft Nasal Spray, generate low-velocity aerosols optimised for improved lung and nasal deposition. They support patient usability, consistent dose delivery, and are particularly suited for liquid formulations such as shear-sensitive biologics and lipid nanoparticles (LNPs).

Resyca provides integrated end-to-end capabilities, from early development and device–formulation integration to clinical supply and commercial manufacturing, including fill-finish. This approach reduces development risk, accelerates timelines, and enables scalable execution.

With advanced platform technologies, strong engineering expertise, and full lifecycle support, Resyca is a strategic partner for next-generation inhaled and nasal drug delivery programmes, including innovative nose-to-brain (CNS) therapies.

Keywords

• Cmc
• Cmo
• Drug-Device Combination Products
• Fill And Finish
• Formulation Development
• Hfa Free
• Inhaler Development
• Medical Device Development
• Nasal Pump Spray
• Nasal Sprays
• Propellant Free Inhalers
• Soft Mist Inhalers

Address

• Headquarters

  Colosseum 237521PV EnschedeOverijssel, Netherlands

Team by function

Based on 3 public job profiles as of 3 September 2026.

• Finance / Accounting1
• Research / R&D1
• Sales1